Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2026)

Amneal Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$124.6 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 10.61% year-over-year to -$124.6 million; the TTM figure through Mar 2026 stood at $9.4 million (down 84.47% YoY), while the FY2025 annual figure was $21.3 million, down 90.93% from the prior year.
• Change in Accured Expenses was -$124.6 million for Q1 2026 at Amneal Pharmaceuticals, down from $18.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $322.7 million in Q2 2022 to a low of -$150.5 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $8.6 million across 5 years, with a median of $33.1 million in 2023.
• Biggest YoY gain for Change in Accured Expenses was 1905.87% in 2022; the steepest drop was 828.86% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at -$55.9 million in 2022, then soared by 64.63% to -$19.8 million in 2023, then soared by 435.29% to $66.3 million in 2024, then sank by 71.96% to $18.6 million in 2025, then plunged by 770.6% to -$124.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$124.6 million (Q1 2026), $18.6 million (Q4 2025), and $69.7 million (Q3 2025), per Business Quant data.